Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1955 1
1956 4
1957 4
1963 3
1965 5
1966 2
1968 1
1970 3
1973 2
1974 1
1975 3
1976 2
1978 8
1979 3
1980 1
1982 1
1983 3
1984 2
1985 1
1986 2
1987 9
1988 5
1989 5
1990 5
1991 5
1993 3
1994 3
1995 3
1996 2
1997 1
1998 3
1999 1
2000 6
2001 4
2002 8
2003 6
2004 3
2005 7
2006 5
2007 7
2008 4
2009 6
2010 7
2011 9
2012 15
2013 10
2014 5
2015 4
2016 3
2017 2
2018 2
2019 2
2020 4
2021 8
2022 6
2023 6
2024 5
2025 8
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Houssiau FA, et al. Among authors: popovic r. Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461. Arthritis Rheum. 2002. PMID: 12209517 Clinical Trial.
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Langerak AW, Chyla B, Popovic R, Jiang Y, Millen R, Lefebure M, Thadani-Mulero M, Boyer M, Seymour JF. Kater AP, et al. Among authors: popovic r. Blood. 2025 Jun 5;145(23):2733-2745. doi: 10.1182/blood.2024025525. Blood. 2025. PMID: 40009494 Free PMC article. Clinical Trial.
Lipid Composition Alters Ferroptosis Sensitivity.
Park VS, Pope LE, Ingram JP, Alchemy GA, Purkal JJ, Murray MB, Jin S, Andino-Frydman EY, Singh S, Chen A, Narayanan P, Kongpachith S, Phillips DC, Dixon SJ, Popovic R. Park VS, et al. Among authors: popovic r. Cancer Res. 2025 Nov 14;85(22):4380-4397. doi: 10.1158/0008-5472.CAN-24-4207. Cancer Res. 2025. PMID: 40911781 Free PMC article.
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Among authors: popovic r. Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. Signal Transduct Target Ther. 2022. PMID: 35185150 Free PMC article.
Large-scale visualization of α-synuclein oligomers in Parkinson's disease brain tissue.
Andrews R, Fu B, Toomey CE, Breiter JC, Lachica J, Beckwith JS, Tian R, Brock EE, Needham LM, Chant GJ, Loiseau C, Deconfin A, Baspin K, Popovic R, Evans J, Goh Y, Kurt B, Senicar L, Edmonds M, Bartels T, Bengoa-Vergniory N, Magill PJ, Jaunmuktane Z, Freeman OJ, Taylor BJM, Hardy J, Lashley T, Ryten M, Vendruscolo M, Wood NW, Weiss LE, Gandhi S, Lee SF. Andrews R, et al. Among authors: popovic r. Nat Biomed Eng. 2025 Oct 1. doi: 10.1038/s41551-025-01496-4. Online ahead of print. Nat Biomed Eng. 2025. PMID: 41034512
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. DiNardo CD, et al. Among authors: popovic r. Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12. Lancet Oncol. 2018. PMID: 29339097 Clinical Trial.
[Drug stability].
Popović R. Popović R. Vojnosanit Pregl. 1978 Jan-Feb;35(1):9-11. Vojnosanit Pregl. 1978. PMID: 644929 Serbian. No abstract available.
[Systemic vasculitis].
Mitrović D, Popović M, Andelković Z, Stefanović D, Popović R. Mitrović D, et al. Among authors: popovic r. Vojnosanit Pregl. 1994 Jan-Feb;51(1):47-53. Vojnosanit Pregl. 1994. PMID: 8553610 Review. Serbian. No abstract available.
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD. Wei AH, et al. Among authors: popovic r. Blood Adv. 2026 Feb 24;10(4):987-998. doi: 10.1182/bloodadvances.2025017083. Blood Adv. 2026. PMID: 41269778 Free PMC article.
231 results